Anika Therapeutics (ANIK) - רווח נקי למניה (EPS TTM)

Steady demand for Inertia injectable solutions supports profitability, which is confirmed by the EPS TTM fundamental metric. High surgeon confidence in regenerative products strengthens the position of Anika Therapeutics, while a neutral geopolitical climate ensures operational security. The current mark of -0.14 characterizes this parameter, allowing investors to assess the company's real capital without quarterly gaps.
ANIK (Anika): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The EPS TTM metric reflects the portion of net income attributable to each common share, allowing investors to assess the actual return on equity without distortions from the volume of issuance. By analyzing the annual EPS TTM snapshot, one can identify the impact of clinical trial costs and government procurement delays for Anika Therapeutics (ANIK), where any sharp deviations in the trend line signal risks of overpaying for the asset.